What we know:
Older persons are at increased risk for COVID-19 respiratory failure for the same reason they are at increased risk for shingles: a decline in T cell immune function as they age.
Decreased T cell immune function leads to increased innate immune responses such as the exuberant inflammation seen in the lungs of some COVID-19 patients.
Antibody responses are often short-lived in patients who have recovered from pathogenic coronaviruses, making them susceptible to repeated infections.
In contrast SARS-CoV infection induces a potent and long-lived T cell response in surviving humans.
Immunization strategies that induce anti-CoV antibodies may worsen COVID-19 pneumonia. Anti-CoV antibodies in animal models have been shown to cause acute lung injury.
Vaccination approaches for COVID-19 in clinical testing are designed to teach the immune system to make antibodies.
Advantage and Applicability of Myeloid Therapeutics ATAK™ Cell Approach as a COVID-19 Vaccine Option
Myeloid cells are a critical regulator of T cell immunity.
In-licensed myeloid technology from Duke Technology harnesses the potent capability of myeloid cells to activate and expand specific T cell populations.
No vaccine or other treatment modality currently exploits this potential.
The ATAK™ Myeloid cell platform is the ﬁrst to harnesses the potential of these cells.
Originally designed for oncology, Myeloid Therapeutic in partnership with Duke University is applying this technology to COVID-19.